Your browser doesn't support javascript.
loading
Screening in serum-derived medium reveals differential response to compounds targeting metabolism.
Abbott, Keene L; Ali, Ahmed; Casalena, Dominick; Do, Brian T; Ferreira, Raphael; Cheah, Jaime H; Soule, Christian K; Deik, Amy; Kunchok, Tenzin; Schmidt, Daniel R; Renner, Steffen; Honeder, Sophie E; Wu, Michelle; Chan, Sze Ham; Tseyang, Tenzin; Greaves, Daniel; Hsu, Peggy P; Ng, Christopher W; Zhang, Chelsea J; Farsidjani, Ali; Gramatikov, Iva Monique T; Matheson, Nicholas J; Lewis, Caroline A; Clish, Clary B; Rees, Matthew G; Roth, Jennifer A; Griner, Lesley Mathews; Muir, Alexander; Auld, Douglas S; Heiden, Matthew G Vander.
Afiliação
  • Abbott KL; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Ali A; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Casalena D; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Do BT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Ferreira R; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Cheah JH; Novartis Institute for BioMedical Research, 181 Massachusetts Avenue, Cambridge, MA 02139, USA.
  • Soule CK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Deik A; Harvard-MIT Health Sciences and Technology, Cambridge, MA 02139, USA.
  • Kunchok T; Department of Genetics, Harvard Medical School, Boston, MA, USA.
  • Schmidt DR; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Renner S; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Honeder SE; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Wu M; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Chan SH; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Tseyang T; Whitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Greaves D; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Hsu PP; Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Ng CW; Novartis Institutes for BioMedical Research, 4056 Basel, Switzerland.
  • Zhang CJ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Farsidjani A; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
  • Gramatikov IMT; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Matheson NJ; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Lewis CA; Whitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Clish CB; Whitehead Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Rees MG; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge CB2 0AW, UK.
  • Roth JA; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK.
  • Griner LM; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
  • Muir A; Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Auld DS; Massachusetts General Hospital Cancer Center, Boston, MA 02113, USA.
  • Heiden MGV; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
bioRxiv ; 2023 Feb 27.
Article em En | MEDLINE | ID: mdl-36909640
ABSTRACT
A challenge for screening new candidate drugs to treat cancer is that efficacy in cell culture models is not always predictive of efficacy in patients. One limitation of standard cell culture is a reliance on non-physiological nutrient levels to propagate cells. Which nutrients are available can influence how cancer cells use metabolism to proliferate and impact sensitivity to some drugs, but a general assessment of how physiological nutrients affect cancer cell response to small molecule therapies is lacking. To enable screening of compounds to determine how the nutrient environment impacts drug efficacy, we developed a serum-derived culture medium that supports the proliferation of diverse cancer cell lines and is amenable to high-throughput screening. We used this system to screen several small molecule libraries and found that compounds targeting metabolic enzymes were enriched as having differential efficacy in standard compared to serum-derived medium. We exploited the differences in nutrient levels between each medium to understand why medium conditions affected the response of cells to some compounds, illustrating how this approach can be used to screen potential therapeutics and understand how their efficacy is modified by available nutrients.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: BioRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Idioma: En Revista: BioRxiv Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
...